Sarepta to Report Q2 Earnings: What's in Store for the Stock?

Key Takeaways SRPT expects Q2 sales of $530M and EPS of $1.11, both up significantly from the prior year.Elevidys sales hit $282M in Q2, though safety issues led to a temporary market withdrawal.SRPT plans $400M in annual savings via layoffs, pipeline reprioritization and restructuring.We expect Sarepta Therapeutics (SRPT) to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s earnings missed estimates by a wider margin in the last reported quarter.The Zacks Consensus Estimate f ...